Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas
European Journal of Cancer2003Vol. 40(7), pp. 963–970
Citations Over TimeTop 11% of 2003 papers
Jakob Anninga, Marc J. van de Vijver, Anne‐Marie Cleton-Jansen, Petra Kristel, A. H. M. Taminiau, M. Nooij, R. Maarten Egeler, Pancras C.W. Hogendoorn
Related Papers
- → Mechanisms of Trastuzumab Resistance and Their Clinical Implications(2005)74 cited
- → Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice(2021)37 cited
- → Is there any cumulative dose for trastuzumab?(2014)3 cited
- → Cytotoxic Effects of Seleno-Trastuzumab, Trastuzumab (Herceptin) and T-DM-1 (Kadcyla) on Trastuzumab Resistant JIMT-1 Breast Cancer Cells(2014)
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer(2016)